{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-22-000105","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2022-07-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.527207+00:00","generated_at":"2026-06-24T20:36:07.703246+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Emergent BioSolutions appoints Sujata Dayal to board; compliance expert joins committees","bullets":["Sujata Dayal appointed Class II director effective July 15, 2022; term expires at 2023 annual meeting.","Also appointed to Nominating and Corporate Governance Committee and Special Committee on Manufacturing and Quality Oversight.","Dayal is VP and Global Chief Compliance Officer at Medline Industries; previously VP healthcare compliance at Johnson & Johnson.","She will receive an initial equity award of $375,000 in RSUs vesting one-third per year for three years.","Dayal is an attorney with expertise in healthcare compliance, regulatory law, and anti-corruption."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-22-000105","json":"https://secwatch.observer/filing/0001367644-22-000105.json","markdown":"https://secwatch.observer/filing/0001367644-22-000105.md","text":"https://secwatch.observer/filing/0001367644-22-000105.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764422000105/0001367644-22-000105-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764422000105/ebs-20220701.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T20:36:07.703246+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b508bbc53b","claim":"Sujata Dayal was appointed as Class II Director at Emergent BioSolutions Inc..","evidence_excerpt":"the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed Sujata Dayal as a Class II director of the Company, effective as of July 15, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764422000105/0001367644-22-000105-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}